Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesNephrologyallcareadvantage sparsentan atrasentan Prior Auth …
    Ask Trek AI about this page
    CurrentallcareadvantagePolicy 134.1

    Renin-Angiotensin System - other agents (sparsentan, atrasentan)

    Customize your policy alerts

    Sign up for allcareadvantage Policy 134.1 alerts

    Get alerted when Policy 134.1 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization policy for coverage of renin-angiotensin system - other agents (Filspari/sparsentan and Vanrafia/atrasentan) for adults with primary IgA nephropathy (IgAN) at risk; governs prescribers, renal specialists, and payer reviewers for AllCare Advantage members.

    Policy Summary
    Payerallcareadvantage
    PolicyRenin-Angiotensin System - other agents (sparsentan, atrasentan)
    Policy CodePolicy 134.1
    Change TypeNo material changes
    Effective DateJun 26, 2025
    Last ReviewJun 26, 2025
    Next Review DateJun 26, 2027
    Key ActionSubmit prior authorization with documentation of primary IgAN at risk, member age ≥18, renal specialist prescriber, failure/contraindication to oral systemic glucocorticoids, and labs showing persistent proteinuria ≥0.5 g/day.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2agents listed (sparsentan, atrasentan)
    6m / 12mapproval length initial / renewal
    ≥18minimum member age for coverage
    ≥0.5 g/daylab threshold required
    Policy Summary
    Payerallcareadvantage
    PolicyRenin-Angiotensin System - other agents (sparsentan, atrasentan)
    Policy CodePolicy 134.1
    Change TypeNo material changes
    Effective DateJun 26, 2025
    Last ReviewJun 26, 2025
    Next Review DateJun 26, 2027
    Key ActionSubmit prior authorization with documentation of primary IgAN at risk, member age ≥18, renal specialist prescriber, failure/contraindication to oral systemic glucocorticoids, and labs showing persistent proteinuria ≥0.5 g/day.
    SourceLink
    On This Page
    Coverage CriteriaClinical & Measurement ThresholdsPrescriber & Prior Authorization RequirementsKey DefinitionsBackground

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    preferred & non-prefformulary status included

    Coverage Criteria

    Initial Therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met

    Initial approval conditions: Member is ≥18 years; diagnosis supported as primary immunoglobulin A nephropathy (IgAN) at risk consistent with the FDA‑approved indication; medication is prescribed by a renal specialist; documentation of failure of or contraindication to initial immunosuppressive therapy with oral systemic glucocorticoids; documentation (laboratory evidence) of persistent proteinuria ≥0.5 g/day despite optimal treatment; if sparsentan is requested and the patient is currently on an ACE inhibitor or ARB, documentation that the ACE inhibitor or ARB will be discontinued; if a non‑preferred agent is requested, documentation of failure of or contraindication to preferred agent(s)see individual nodes

    Approve up to 6 months if all conditions met

    Continuation/Renewal Therapy — Renewal covered when ALL of the following are met

    Renewal covered when ALL of the following are met

    Renewal conditions: Member met the initial approval criteria at baseline; documentation in chart notes demonstrates clinical efficacy (for example, reduction in proteinuria or improvement/stable kidney function compared with baseline)clinical improvement or stability

    Approve up to 12 months if met

    Requests for renin-angiotensin system — other agents (including sparsentan/Vanrafia) where the submitted diagnosis is not primary immunoglobulin A nephropathy (IgAN) at risk are excluded from coverage and should be denied. Documentation must support the FDA‑approved indication of primary IgAN at risk to meet policy criteria.

    Use does not meet criteria (and should be denied) when required clinical thresholds or prerequisites are not documented. Examples include: missing laboratory evidence of persistent proteinuria ≥0.5 g/day despite optimal treatment; lack of documentation of failure of or contraindication to initial immunosuppressive therapy with oral systemic glucocorticoids; absence of a renal specialist prescriber; or failure to document contraindication/failure to preferred agents when a non‑preferred agent is requested.

    Additional denial scenarios specific to sparsentan include failure to document that an ACE inhibitor or ARB will be discontinued when sparsentan is being initiated in a patient currently receiving one. Renewal requests are denied if the member did not meet initial criteria or if chart documentation does not show clinical efficacy (for example, reduction in proteinuria or stable/improved kidney function compared to baseline).

    Clinical & Measurement Thresholds

    Proteinuria (urine) — thresholds
    Policy proteinuria thresholdPersistent proteinuria ≥0.5 g/day despite optimal treatment (policy requirement for initial approval)
    UPCR referenced thresholdUrine protein-to-creatinine ratio (UPCR) ≥1.5 g/g noted as the typical threshold for ‘at risk of rapid disease progression’ in Vanrafia prescribing information
    Documentation requirementLaboratory documentation (eg, 24‑hour urine or equivalent) must support persistent proteinuria ≥0.5 g/day despite optimal therapy
    Age
    Minimum member age≥18 years
    Consequence if under ageRequests for members <18 years do not meet criteria and should be forwarded for MD review or denied per criteria flow

    Prescriber & Prior Authorization Requirements

    Prior Authorization

    Prior authorization required; time-limited approvals

    Prior authorization is required for these agents. Initial approvals are granted for up to 6 months; renewals may be approved for up to 12 months only if renewal criteria are met (member met initial criteria at baseline and documentation of clinical efficacy is provided).

    Step Therapy

    Step therapy: document prior therapy failure or contraindication

    Document failure of or contraindication to initial immunosuppressive therapy with oral systemic glucocorticoids before approval; if a non-preferred agent is requested, document failure or contraindication to preferred agent(s). For sparsentan, if the patient is currently on an ACE inhibitor or ARB, document that the ACE inhibitor or ARB will be discontinued.

    • Failure/contraindication to initial oral systemic glucocorticoids required (Criteria #5).
    • Non-preferred agent requests require documentation of failure/contraindication to preferred agents (Criteria #8).
    • If sparsentan and patient on ACE inhibitor/ARB, documentation that ACE inhibitor/ARB will be discontinued (Criteria #7).

    Key Definitions

    ‘At risk / at risk of rapid disease progression’ — definition
    Clinical concept - definition‘At risk’ or ‘at risk of rapid disease progression’ is the FDA‑referenced clinical concept for IgAN indications
    Typical UPCR for rapid progression (source)Vanrafia prescribing information generally defines ‘at risk of rapid disease progression’ as UPCR ≥1.5 g/g
    Policy linkagePolicy requires diagnosis of primary IgA nephropathy that is ‘at risk’ for use of these agents

    Background

    Sparsentan (Filspari) is indicated to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk for disease progression. The policy applies to adults aged ≥18 years and requires prior authorization for initiation (approvals up to 6 months) and renewal (approvals up to 12 months) contingent on meeting the coverage criteria and documentation of clinical benefit such as reduced proteinuria or stable/improved kidney function.

    Documentation Required

    Documentation required with prior authorization

    Include documentation that the diagnosis is primary IgA nephropathy (IgAN) at risk, member is ≥18 years old, and that the medication is prescribed by a renal specialist. Provide chart evidence of failure or contraindication to initial oral systemic glucocorticoids and laboratory documentation of persistent proteinuria ≥0.5 g/day despite optimal treatment. For sparsentan, include documentation that an ACE inhibitor or ARB will be discontinued. For non-preferred agents, include prior failure/contraindication to preferred agents.

    • Diagnosis consistent with primary IgA nephropathy (IgAN) at risk (Criteria #3).
    • Member age ≥18 years (Criteria #2).
    • Prescriber specialty: renal specialist (Criteria #4).
    • Failure/contraindication to oral systemic glucocorticoids (Criteria #5).
    • Laboratory evidence of persistent proteinuria ≥0.5 g/day despite optimal treatment (Criteria #6).
    • If sparsentan, documentation that ACE inhibitor or ARB will be discontinued (Criteria #7).
    • If requesting a non-preferred agent, documentation of failure/contraindication to preferred agents (Criteria #8).
    Denial Risk

    Triggers that may lead to denial

    Denial may be triggered when required criteria or documentation are not met, including member age <18 years, diagnosis not consistent with primary IgAN at risk, medication not prescribed by a renal specialist, lack of documented failure/contraindication to initial oral systemic glucocorticoids, missing lab evidence of persistent proteinuria ≥0.5 g/day despite optimal treatment, failure to discontinue ACE inhibitor/ARB when sparsentan is used, or lack of failure/contraindication documentation for non-preferred agents.

    • Member <18 years (Criteria #2 = does not meet criteria).
    • Diagnosis not supportive of primary IgAN at risk (Criteria #3 = deny).
    • Medication not prescribed by a renal specialist (Criteria #4 = deny).
    • No documentation of failure/contraindication to oral systemic glucocorticoids (Criteria #5 = deny).
    • No lab documentation of persistent proteinuria ≥0.5 g/day despite optimal treatment (Criteria #6 = deny).
    • If sparsentan and ACE inhibitor/ARB not discontinued, deny (Criteria #7 = deny).
    • Non-preferred agent without documented failure/contraindication to preferred agents (Criteria #8 = deny).